[Skip to Content]
[Skip to Content Landing]
Correspondence
October 20, 2008

Recurrent Hyperglycemia During Adalimumab Treatment in a Patient With Psoriasis

Arch Dermatol. 2008;144(10):1403-1404. doi:10.1001/archderm.144.10.1403

Tumor necrosis factor (TNF) inhibitors are increasingly used in psoriasis treatment. We describe a patient with psoriasis and diabetes mellitus (DM) who developed recurrent hyperglycemia during adalimumab treatment.

The patient presented in 1999 at age 31 years with a 4-year history of psoriasis and psoriatic spondylarthritis. Different systemic treatments, including UV-B, efalizumab, cyclosporine, and acitretin were tried but were discontinued owing either to toxic effects or lack of efficacy. Photochemotherapy proved most effective, but the patient discontinued therapy owing to its inconvenience.

First Page Preview View Large
First page PDF preview
First page PDF preview
×